Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor

Journal of Virology

Volumn 84, Issue 18, 2010, Pages 9359-9368

  Zhu, Yun ^a   Lu, Lu ^b   Xu, Liling ^a   Yang, Hengwen ^a   Jiang, Shibo ^b   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; ENFUVIRTIDE; GLYCOPROTEIN GP 41; P 20; TROPONIN I TYPE 3 INTERACTING KINASE LIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PEPTIDE; PROTEIN BINDING; TNNI3K PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DNA LIBRARY; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS A; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SYNCYTIUM; TWO HYBRID SYSTEM; VESICULAR STOMATITIS VIRUS; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS STRAIN; YEAST; AMINO ACID SEQUENCE; CELL CULTURE; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; VIROLOGY; VIRUS ENTRY;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MAP KINASE KINASE KINASES; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; TWO-HYBRID SYSTEM TECHNIQUES; VIRUS INTERNALIZATION;

EID: 77956021159     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00644-10     Document Type: Article

References (57)

1. Blumenthal, R., and D. S. Dimitrov. 2007. Targeting the sticky fingers of HIV-1. Cell 129:243-245.
2. Brass, A. L., D. M. Dykxhoorn, Y. Benita, N. Yan, A. Engelman, R. J. Xavier, J. Lieberman, and S. J. Elledge. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926.
3. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
4. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
5. Chang, L. J., V. Urlacher, T. Iwakuma, Y. Cui, and J. Zucali. 1999. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6:715-728.
6. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
7. D'Anna, J. A., R. A. Tobey, and L. R. Gurley. 1980. Concentration- dependent effects of sodium-butyrate in Chinese-hamster cells-cell-cycle progression, inner-histone acetylation, histone H-1 dephosphorylation, and induction of an H1-like protein. Biochemistry 19:2656-2671.
8. Dimitrov, D. S. 1997. How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell 91:721-730.
9. Dwyer, J. J., K. L. Wilson, K. Martin, J. E. Seedorff, A. Hasan, R. J. Medinas, D. K. Davison, M. D. Feese, H. T. Richter, H. Kim, T. J. Matthews, and M. K. Delmedico. 2008. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci. 17:633-643.
10. Eggink, D., C. E. Baldwin, Y. Deng, J. P. Langedijk, M. Lu, R. W. Sanders, and B. Berkhout. 2008. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 82:6678-6688. (Pubitemid 351875144)
11. Geitmann, M., T. Unge, and U. H. Danielson. 2006. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J. Med. Chem. 49:2375-2387.
12. Goila-Gaur, R., and K. Strebel. 2008. HIV-I Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51.
13. Golding, H., M. Zaitseva, E. de Rosny, L. R. King, J. Manischewitz, I. Sidorov, M. K. Gorny, S. Zolla-Pazner, D. S. Dimitrov, and C. D. Weiss. 2002. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76:6780-6790.
14. Gorny, M. K., and S. Zolla-Pazner. 2000. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J. Virol. 74:6186-6192.
15. Greenberg, M. L., and N. Cammack. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54:333-340.
16. Guo, Y., E. Rumschlag-Booms, J. Wang, H. Xiao, J. Yu, L. Guo, G. F. Gao, Y. Cao, M. Caffrey, and L. Rong. 2009. Analysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza. Virol. J. 6:39.
17. Huang, J. H., Z. Q. Liu, S. Liu, S. Jiang, and Y. H. Chen. 2006. Identification of the HIV-1 gp41 core-binding motif-HXXNPF. FEBS Lett. 580:4807-4814.
18. Huang, J. H., Z. Qi, F. Wu, L. Kotula, S. B. Jiang, and Y. H. Chen. 2008. Interaction of HIV-1 gp41 core with NPF motif in Epsin-implication in endocytosis of HIV. J. Biol. Chem. 283:14994-15002.
19. Huang, J. H., H. W. Yang, S. Liu, J. Li, S. Jiang, and Y. H. Chen. 2007. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. Biochem. J. 403:565-571.
20. Jiang, S., and A. K. Debnath. 2000. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. Biochem. Biophys. Res. Commun. 269:641-646.
21. Jiang, S., K. Lin, and M. Lu. 1998. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 72:10213-10217.
22. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
23. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem. Biophys. Res. Commun. 195:533-538.
24. Jiang, S., K. Lin, L. Zhang, and A. K. Debnath. 1999. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 80:85-96.
25. Jiang, S. B., K. Lin, and A. R. Neurath. 1991. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174:1557-1563.
26. Kilby, J. M., and J. J. Eron. 2003. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348:2228-2238.
27. König, R., Y. Y. Zhou, D. Elleder, T. L. Diamond, G. M. C. Bonamy, J. T. Irelan, C. Y. Chiang, B. P. Tu, P. D. De Jesus, C. E. Lilley, S. Seidel, A. M. Opaluch, J. S. Caldwell, M. D. Weitzman, K. L. Kuhen, S. Bandyopadhyay, T. Ideker, A. P. Orth, L. J. Miraglia, F. D. Bushman, J. A. Young, and S. K. Chanda. 2008. Global analysis of host-pathogen interactions that regulate early stage HIV-1 replication. Cell 135:49-60.
28. Labrosse, B., L. Morand-Joubert, A. Goubard, S. Rochas, J. L. Labernardiere, J. Pacanowski, J. L. Meynard, A. J. Hance, F. Clavel, and F. Mammano. 2006. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 80:8807-8819.
29. Li, B., and S. Fields. 1993. Identification of mutations in P53 that affect its binding to SV40 large T-antigen by using the yeast 2-hybrid system. FASEB J. 7:957-963. (Pubitemid 23225555)
30. Li, J., X. Chen, J. Huang, S. Jiang, and Y. H. Chen. 2009. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. Immunobiology 214:51-60.
31. Li, L., L. He, S. Tan, X. Guo, H. Lu, Z. Qi, C. Pan, X. An, S. Jiang, and S. Liu. 2010. 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob. Agents Chemother. 54:1700-1711.
32. Liu, S., S. Wu, and S. Jiang. 2007. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 13:143-162.
33. Liu, S. W., H. Lu, J. Niu, Y. J. Xu, S. G. Wu, and S. B. Jiang. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280:11259-11273.
34. Liu, S. W., Q. Zhao, and S. B. Jiang. 2003. Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides 24:1303-1313.
35. Liu, Z., and Y. H. Chen. 2004. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy. J. Immunol. Methods 285:93-97.
36. Lu, J., S. G. Deeks, R. Hoh, G. Beatty, B. A. Kuritzkes, J. N. Martin, and D. R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV- 1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43:60-64.
37. Lu, L., Y. Zhu, J. H. Huang, X. Chen, H. W. Yang, S. B. Jiang, and Y. H. Chen. 2008. Surface exposure of the HIV-1 Env cytoplasmic tail LLP2 domain during the membrane fusion process-interaction with gp41 fusion core. J. Biol. Chem. 283:16723-16731.
38. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
39. Miyauchi, K., Y. Kim, O. Latinovic, V. Morozov, and G. B. Melikyan. 2009. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433-444.
40. Neurath, A. R., N. Strick, S. Jiang, Y. Y. Li, and A. K. Debnath. 2002. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2:6.
41. Qiao, Z. S., M. Kim, B. Reinhold, D. Montefiori, J. H. Wang, and E. L. Reinherz. 2005. Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration. J. Biol. Chem. 280:23138-23146.
42. Rich, R. L., and D. G. Myszka. 2007. Survey of the year 2006 commercial optical biosensor literature. J. Mol. Recognit. 20:300-366.
43. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
44. Root, M. J., M. S. Kay, and P. S. Kim. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888.
45. Roymans, D., H. L. De Bondt, E. Arnoult, P. Geluykens, T. Gevers, M. Van Ginderen, N. Verheyen, H. Kim, R. Willebrords, J. F. Bonfanti, W. Bruinzeel, M. D. Cummings, H. van Vlijmen, and K. Andries. 2010. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl. Acad. Sci. U. S. A. 107:308-313.
46. Sista, P. R., T. Melby, D. Davison, L. Jin, S. Mosier, M. Mink, E. L. Nelson, R. DeMasi, N. Cammack, M. P. Salgo, T. J. Matthews, and M. L. Greenberg. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:1787-1794.
47. Tan, K., J. Liu, J. Wang, S. Shen, and M. Lu. 1997. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 94:12303-12308.
48. Towers, G. J. 2007. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4:40.
49. Wang, H. T., Z. Qi, A. G. Guo, Q. C. Mao, H. Lu, X. L. An, C. L. Xia, X. J. Li, A. K. Debnath, S. G. Wu, S. W. Liu, and S. B. Jiang. 2009. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob. Agents Chemother. 53:4987-4998.
50. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
51. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
52. Wild, C., T. Greenwell, and T. Matthews. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retrovir. 9:1051-1053.
53. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91:9770-9774.
54. Xu, J. Y., M. K. Gorny, T. Palker, S. Karwowska, and S. Zolla-Pazner. 1991. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65:4832-4838.
55. Xu, L., S. Hue, S. Taylor, D. Ratcliffe, J. A. Workman, S. Jackson, P. A. Cane, and D. Pillay. 2002. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 16:1684-1686. (Pubitemid 34921116)
56. Yeung, M. L., L. Houzet, V. S. R. K. Yedavalli, and K. T. Jeang. 2009. A genome-wide short hairpin RNA screening of Jurkat T-cells for human proteins contributing to productive HIV-1 replication. J. Biol. Chem. 284: 19463-19473.
57. Zhang, M. Y., V. Choudhry, I. A. Sidorov, V. Tenev, B. K. Vu, A. Choudhary, H. Lu, G. M. Stiegler, H. W. Katinger, S. Jiang, C. C. Broder, and D. S. Dimitrov. 2006. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J. Immunol. Methods 317:21-30.